NEUROCRINE BIOSCIENCES INC business relationships
Companies named in NEUROCRINE BIOSCIENCES INC’s 10-K filed 2026-02-11, and public companies whose annual reports name NEUROCRINE BIOSCIENCES INC. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 6.1 / 10
- AI naming
- 100 / 100 Top 1% in its category
- Agent readiness
- 5 / 100
- AI adoption
- 0 / 100
Layers: PeptidesGLP-1 & obesity
Named in NEUROCRINE BIOSCIENCES INC’s annual report 6
“Additionally, we are entitled to receive royalties from Takeda on the future net sales of osavampator in Japan.” SEC filing
“Osavampator was in-licensed from Takeda Pharmaceutical Company Limited (Takeda) in 2020, and we have exclusive worldwide rights to develop and commercialize osavampator, except in Japan, where Takeda has exclusive development and commercialization rights.” SEC filing
“Under the terms of our license agreement with Sanofi, Sanofi may be entitled to receive potential future payments of up to $ 10.0 million upon the achievement of certain event-based milestones and is entitled to receive royalties at tiered percentage rates ranging from 3.0 % to 5.0 % on our future n...” SEC filing
“Amendment No. 1 to Collaboration and License Agreement dated June 14, 2019 between Voyager Therapeutics, Inc. and the Company” SEC filing
“NBI‑921355 was in-licensed from Xenon Pharmaceuticals Inc. in 2019, and we retain global rights.” SEC filing
“...udes U.S. Food and Drug Administration (FDA) approved treatments for tardive dyskinesia (TD), chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (CAH), and endometriosis and uterine fibroids in collaboration with AbbVie Inc. (AbbVie).” SEC filing
Companies whose annual reports name NEUROCRINE BIOSCIENCES INC 6
“| Neurocrine Biosciences | | U.S. | | Collaboration to develop and commercialize 7 compounds in Takeda's early-to-mid stage neuroscience pipeline, including TAK-041/NBI-1065846, TAK-653/NBI-1065845 and TAK-831/NBI-1065844 (luvadaxistat).” SEC filing
“First Amendment to Collaboration and License Agreement, by and between Registrant and Neurocrine Biosciences, Inc., dated April 3, 2024.” SEC filing
“| | ● | | our strategic collaborations and licensing agreements with, and funding from, our collaboration partners Neurocrine Biosciences, Inc. and Novartis Pharma AG and our licensee Alexion, AstraZeneca Rare Disease (successor-in-interest to former licensee Pfizer Inc.); |” SEC filing
“...llaborators' clinical product candidates, which include azetukalner and NBI-921355 (being developed by our collaborator Neurocrine Biosciences), along with product candidates we expect to enter clinical development, which include our pre-clinical compounds, are in varying stages of development and w...” SEC filing
“In May 2024, we exclusively licensed our ATXN2 program to Neurocrine Biosciences, Inc. As consideration for such license, we received upfront payment, and we will be eligible to receive milestone payments upon the completion of certain regulatory, development and commercial achievements, as well as...” SEC filing
“In May 2024, the Company entered into an exclusive license agreement with Neurocrine Biosciences, Inc., or Neurocrine, pursuant to which the Company granted Neurocrine an exclusive worldwide license to a discovery research program targeting ATXN2, or the Neurocrine License Agreement.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.